| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:18 | PPARα activation in utero leading to impaired fertility in males | Reproductive system disease | Under Review | Human, Rat, Mouse | 0.12 | KE:289 | Decrease, Translocator protein (TSPO) |
| AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal system disease | Under Development | Humans | 0.12 | KE:288 | Activation of specific nuclear receptors, Transcriptional change |
| AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal system disease | Under Review | Rattus sp. ABTC 42503, Mus sp. 2000082 | 0.4 | KE:853 | Changes/Inhibition, Cellular Homeostasis and Apoptosis |
| KE:139 | N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects | ||||||
| AOP:48 | Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. | Developmental disorder of mental health | WPHA/WNT Endorsed | Human, Mouse, Rat | 0.11 | KE:352 | N/A, Neurodegeneration |
| AOP:64 | Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility | Reproductive system disease | - | Rattus norvegicus | 0.14 | KE:496 | Increased apoptosis, decreased fetal/adult Leydig Cells |
| AOP:96 | Axonal sodium channel modulation leading to acute mortality | Unclassified | - | Insects, Fish | 0.17 | KE:602 | Increased, Ataxia, paralysis, or hyperactivity |
| AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive system disease; Cancer | - | Rattus norvegicus | 0.17 | KE:111 | Agonism, Estrogen receptor |
| AOP:113 | Glutamate-gated chloride channel activation leading to acute mortality | Unclassified | - | Bombus impatiens, Chaetanaphothrips orchidii, Radopholus similis, Daphnia magna, Orius insidiosus, Hymenoptera, Helicoverpa zea, Lepidoptera, Liriomyza trifolii, Orius isidiosus, Acyrthosiphon kondoi | 0.17 | KE:764 | N/A, Ataxia, paralysis, or hyperactivity |
| AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive system disease | - | Caenorhabditis elegans | 0.12 | KE:1262 | Apoptosis |
| AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive system disease | WPHA/WNT Endorsed | Rat, Human, Mouse | 0.17 | KE:1262 | Apoptosis |
| AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal system disease | WPHA/WNT Endorsed | Rodents, Homo sapiens | 0.2 | KE:1393 | Hepatocytotoxicity |
| AOP:279 | Microtubule interacting drugs lead to peripheral neuropathy | Nervous system disease | - | 0.25 | KE:1582 | Impaired axonial transport | |
| AOP:327 | Excessive reactive oxygen species production leading to mortality (1) | Unclassified | - | Daphnia magna | 0.2 | KE:1769 | Increase, Body fluid overload |
| AOP:333 | Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation | Unclassified | - | 0.2 | KE:1446 | Decrease, Coupling of oxidative phosphorylation | |
| AOP:374 | Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on brain cells (neuronal and non-neuronal) leads to neuroinflammation resulting in encephalitis | Nervous system disease | Under Development | Human | 0.25 | KE:352 | N/A, Neurodegeneration |
| AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory system disease | - | 0.25 | KE:1262 | Apoptosis | |
| AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic disease; Cancer | Under Development | Humans, Mice | 0.22 | KE:1971 | Increased, tumor growth |
| KE:1262 | Apoptosis | ||||||
| AOP:441 | Ionizing radiation-induced DNA damage leads to microcephaly via apoptosis and premature cell differentiation | Congenital nervous system abnormality; Nervous system disease | - | Homo sapiens, Mus musculus musculus, Rattus norvegicus | 0.14 | KE:1262 | Apoptosis |
| AOP:443 | DNA damage and mutations leading to Metastatic Breast Cancer | Thoracic disease; Cancer | Under Development | Human and other cells in culture, Human, Mice, Rat, Canine heartworm nematode, Yeast | 0.1 | KE:112 | Antagonism, Estrogen receptor |
| AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory system disease | - | 0.05 | KE:1262 | Apoptosis | |
| AOP:447 | Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways | Urinary system disease | - | 0.08 | KE:1097 | Occurrence, renal proximal tubular necrosis | |
| AOP:450 | Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality | Nervous system disease | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.14 | KE:352 | N/A, Neurodegeneration |
| AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory system disease | - | 0.09 | KE:1262 | Apoptosis | |
| AOP:460 | Antagonism of Smoothened receptor leading to orofacial clefting | Unclassified | Under Development | Mouse | 0.11 | KE:1262 | Apoptosis |
| AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal system disease | - | 0.09 | KE:1262 | Apoptosis | |
| AOP:465 | Alcohol dehydrogenase leading to reproductive dysfunction | Unclassified | - | 0.12 | KE:748 | Increased, Estrogen receptor (ER) activity | |
| AOP:470 | Deposition of energy leads to abnormal vascular remodeling | Cardiovascular system disease | Under Review | Human, Rat, Mouse, Rabbit | 0.12 | KE:2244 | Altered Stress Response Signaling |
| AOP:472 | DNA adduct formation leading to kidney failure | Urinary system disease | - | 0.11 | KE:1097 | Occurrence, renal proximal tubular necrosis | |
| AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental disorder of mental health | Under Review | Mouse, Rat, Rabbit, Dog, Pigs, Cow, Human | 0.12 | KE:2244 | Altered Stress Response Signaling |
| AOP:491 | Decrease, GLI1/2 target gene expression leads to orofacial clefting | Unclassified | Under Development | Mouse | 0.17 | KE:1262 | Apoptosis |
| AOP:495 | Androgen receptor activation leading to prostate cancer | Reproductive system disease; Cancer | - | 0.11 | KE:1183 | Decreased, Apoptosis (Epithelial Cells) | |
| AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental disorder of mental health | - | Rattus norvegicus, Mus musculus, Homo sapiens | 0.29 | KE:352 | N/A, Neurodegeneration |
| KE:1262 | Apoptosis | ||||||
| AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental disorder of mental health | - | Mouse, Human | 0.11 | KE:1262 | Apoptosis |
| AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.11 | KE:1262 | Apoptosis | |
| AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive system disease; Endocrine system disease | - | Rat, Mouse, Zebra fish, Human | 0.17 | KE:1262 | Apoptosis |
| AOP:569 | Decreased DNA methylation of FAM50B/PTCHD3 leading to IQ loss of children via PI3K-Akt pathway | Developmental disorder of mental health | - | 0.17 | KE:2195 | Increase, CNS Neural cell death |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:12 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging | Nervous system disease; Developmental disorder of mental health | WPHA/WNT Endorsed | Monkey, Rat, Human, Mouse, Zebrafish | 0.12 | KE:352 | N/A, Neurodegeneration |
| AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | Homo sapiens, Mus musculus | 0.25 | KE:885 | Increase, Cancer |
| AOP:205 | AOP from chemical insult to cell death | Unclassified | - | Vertebrates | 0.17 | KE:1262 | Apoptosis |
| AOP:260 | CYP2E1 activation and formation of protein adducts leading to neurodegeneration | Nervous system disease | - | Human | 0.14 | KE:1514 | Neurodegeneration |
| AOP:270 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired locomotor activity | Unclassified | - | 0.12 | KE:10016 | Impaired locomotor activity | |
| AOP:281 | Acetylcholinesterase Inhibition Leading to Neurodegeneration | Nervous system disease | - | 0.1 | KE:352 | N/A, Neurodegeneration | |
| AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:498 | Increased LCN2/iron complex leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.5 | KE:2150 | Neurological disorder |
| KE:191 | Neuronal dysfunction | ||||||
| AOP:501 | Excessive iron accumulation leading to neurological disorders | Nervous system disease | - | Homo sapiens | 0.25 | KE:2150 | Neurological disorder |
| AOP:504 | SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level | Unclassified | - | Mammals | 0.33 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | Human, Mouse, Rat | 0.2 | KE:885 | Increase, Cancer |
| AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | Human, Mouse, Rat | 0.2 | KE:885 | Increase, Cancer |
| AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | Vertebrates | 0.33 | KE:885 | Increase, Cancer |
| KE:1446 | Decrease, Coupling of oxidative phosphorylation | ||||||
| AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | Human and other cells in culture | 0.2 | KE:885 | Increase, Cancer |
| AOP:561 | Aromatase induction leading to estrogen receptor alpha activation via increased estradiol | Unclassified | - | Vertebrates | 0.2 | KE:1065 | Activation, estrogen receptor alpha |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:30 | Estrogen receptor antagonism leading to reproductive dysfunction | Unclassified | Under Review | Zebra danio, Fathead minnow, Medaka | 0.17 | KE:112 | Antagonism, Estrogen receptor |
| AOP:118 | Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal system disease | - | Mus musculus, Rattus norvegicus | 0.25 | KE:786 | Increase, Cytotoxicity (hepatocytes) |
| AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive system disease; Cancer | - | Mouse, Homo sapiens | 0.29 | KE:1065 | Activation, estrogen receptor alpha |
| KE:1064 | prepubertal increase, Estrogen receptor (ER) activity | ||||||
| AOP:263 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Mouse, Rat, Lemna minor, Human, Caenorhabditis elegans | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation |
| AOP:264 | Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death | Unclassified | Under Development | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation | |
| AOP:265 | Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium | Unclassified | Under Development | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation | |
| AOP:266 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity | Unclassified | Under Development | 0.17 | KE:1446 | Decrease, Coupling of oxidative phosphorylation | |
| AOP:267 | Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion | Unclassified | Under Development | 0.2 | KE:1446 | Decrease, Coupling of oxidative phosphorylation | |
| AOP:268 | Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling | Unclassified | Under Development | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation | |
| AOP:314 | Binding to estrogen receptor (ER)-α in immune cells leading to exacerbation of systemic lupus erythematosus (SLE) | Immune system disease; Musculoskeletal system disease | Under Development | Homo sapiens | 0.2 | KE:1710 | Binding to estrogen receptor (ER)-α in immune cells |
| AOP:440 | Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia | Benign neoplasm; Endocrine system disease; Reproductive system disease; Reproductive system disease; Cancer; Endocrine system disease | Under Development | Human, Rat, Mice | 0.22 | KE:1046 | Suppression, Estrogen receptor (ER) activity |
| KE:1973 | Increased, estrogens | ||||||
| AOP:445 | Estrogen Receptor Alpha Agonism leads to Impaired Reproduction | Reproductive system disease | - | 0.12 | KE:1065 | Activation, estrogen receptor alpha | |
| AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired metabolic disease | - | Mus musculus, Homo sapiens | 0.1 | KE:2126 | Estrogen receptor alpha inactivation |
| AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited metabolic disorder; Disease of metabolism | - | 0.12 | KE:2126 | Estrogen receptor alpha inactivation | |
| AOP:503 | Activation of uterine estrogen receptor-alfa leading to endometrial adenocarcinoma, via epigenetic modulation | Reproductive system disease; Cancer | Under Review | Human, Mouse | 0.17 | KE:1065 | Activation, estrogen receptor alpha |
| AOP:536 | Estrogen receptor agonism leading to reduced survival and population growth due to renal failure | Unclassified | - | 0.17 | KE:111 | Agonism, Estrogen receptor | |
| AOP:537 | Estrogen receptor agonism leads to reduced fecundity via increased vitellogenin in the liver | Unclassified | - | 0.2 | KE:111 | Agonism, Estrogen receptor |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.